References
- Monahan BP, Allegra CJ. Antifolates. In: Chabner BA, Longo DL, editors. Cancer chemotherapy & biotherapy: principles & practices, 4th ed. New York: Lippincott Williams & Wilkins, 2006: 92-124.
- Chabner BA, Ryan DP, Paz-Ares L, Garcia-Carbonero R, Calabresi P. Antineoplastic agents. In: Hardman JG, Limbird LE, editors. Goodman & Gilman's the pharmacological basis of therapeutics, 10th ed. New York: McGraw-Hill Medical Publishing Division, 2001: 1399-1404.
- Treon SP, Chabner BA. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996; 42; 8(B): 1322-1329.
- DeVita VT, Jr, Hellman S, Rosenberg SA. Cancer: principles & practice of oncology, 7th ed. Philadelphia: Lippincott Williams & Wilkins, 2005.
- Micromedex® Healthcare Series: Thomson Micromedex, Greenwood Village, Colorado, 2006.
- Crom WR, Pratt CB, Green AA, Champion JE, Crom DB, Stewart CF et al. The effect of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate. J Clin Oncol 1984; 2: 655-661.
- Josting A, Diehl V, Engert A. Methotrexat: Pharmakologie, Toxizität und Rescue-massnahmen bei hochdosier ter Behandlung. Onkologe 1998; 4: 974-985.
- Solimando DA. Drug information handbook for oncology, 5th ed. Drug Information Series, Lexi-Comp. Inc, 2005.
- British Naional Formulary 55, BMJ Group and RPS Publishing, 2008.
- Bleyr WA. The clinical pharmacology of methotrexate: new applications of an old drug. Cancer 1978; 41: 36-51.
- Cova D, Lorusso V, Silvestris N. The pharmacokinetics and pharmacodynamics of drugs in elderly cachectic (cancer) patients. In: Mantovani G. Cachexia and Wasting: A Modern Approach. Springer Milan, 2006: 377-382.
- Undevia SD, Gomez-Abuin G, Ratain MJ. Pharmacokinetic variability of snticancer agents. Nat Rev Cancer 2005; 5:447-458.
- Fleming RF, Eldridge RM, Johnson CE, Stewart CF. Disposition of high-dose methotrexate in an obese cancer patient. Cancer 1991; 68: 1247-1250.
- Abdah-Bortnyak R, Tsalic M, Haim N. Actual body weight for determining doses of chemotherapy in obese cancer patients. Med Oncol 2003; 20: 363-367.
- Jaehde U, Kloft C. Dosis-Individualisierung in der Krebs-Chemotherapie. Pharm Unserer Zeit 2006; 2: 150-156.
- Skaerby T, Joensson P, Hjorth L, Behrentz M, Bjoerk O, Forestier E et al. High-dose methotrexate: on the relationship of methotrexate elimination time vs renal function and serum methotrexate levels in 1164 courses in 264 Swedish children with acute lymphoblastic leukaemia (ALL). Cancer Chemother and Pharmacol 2003; 51: 311-320.
- Bauters TGM, Verlooy J, Robays H, Laureys G. Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm World Sc 2008; 30(3).
- Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J. Potential interaction between methotrexate and omeprazole. Ann Pharmacother 2000; 34: 1024-1027.
- Hon ZZ, Evans WE. Making TDM work to optimize cancer chemotherapy: a multidisciplinary team approach. Clin Chem 1998; 44: 388-400.
- Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006; 11: 694-703.
- Esteve MA, Devictor-Pierre B, Galy G, Andre N, Coze C, Lacarelle B et al. Severe acute toxicity assiciated with high-dose methotrexate (MTX) therapy: use of therapeutic drug monitoring and test-dose to guide carboxypeptidase G2 rescue and MTX continuation. Eur J Clin Pharmacol 2007; 63: 39-42.